AMP German Cannabis Group (CSE: XCX) (Frankfurt: C4T) has signed a medical cannabis distribution agreement with CC Pharma GmbH, a subsidiary of Aphria (NYSE: APHA) (TSX: APHA).
CC Pharma is a distributor of EU-pharmaceuticals products to more than 13,000 pharmacies throughout Germany. The company holds 318 active German national pharmaceutical licenses and 692 active EU pharmaceutical licenses.
AMP has signed the four-year agreement through its AMP Alternative Medical Products GmbH subsidiary. Under the agreement, AMP will supply CC Pharma with medical cannabis cultivated in Canada. The agreement calls for monthly shipments of imported EU-GMP certified medical cannabis products starting in mid-2020 upon AMP meeting the contract’s preconditions, including receiving a narcotic license to import and distribute EU-GMP cannabis in Germany.
“This strategic relationship will establish AMP as an important importer of medical cannabis into Germany in the future,” stated Dr. Stefan Feuerstein, managing director of AMP Germany.
AMP is bullish on the Germany cannabis market. The company has entered into two supply contracts and is in talks with several Canadian producers for EU-GMP certified cannabis for import into Germany from Canada.
“Currently, only three Canadian and one Dutch producer of EU-GMP medical cannabis supply the German market in a meaningful way,” stated Alex Blodgett, the CEO of AMP.
